Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term
N
-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Clin Ther. 2000;22:209 - 221.
Hansen NCG, Skriver A, Brorsen-Riis L, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Respir Med. 1994;88:531 - 535.
Grassi C, Casali L, Rossi A, et al. A comparison between different methods for detecting bronchial hyperreactivity. Bronchial hyperreactivity: methods of study.
Eur J Respir Dis Suppl.
1980;106:19 - 27.
Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.
Eur J Clin Pharmacol. 1976;9:393 - 396.
Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy?
Eur Respir J. 1994;7:94 - 101.
Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Eur Respir J. 1988;1:351 - 355.
Parr GD, Huitson A. Oral fabrol (oral N-acetylcysteine) in chronic bronchitis.
Br J Dis Chest. 1987;81:341 - 348.
Boman G, Bcker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis. 1983;64:405 - 415.
Verstraeten JM. Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparaive clinical trial with N-acetylcysteine, bromhexine and placebo.
Acta Tuberc Pneumol Belg. 1979;70:71 - 80.
Pizzulli L, Hagendorff A, Zirbes M, et al. N-acetylcysteine attenuates nitroglycerin tolerance in patients with angina pectoris and normal left ventricular function.
Am J Cardiol. 1997;79:28 - 33.
Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris.
J Am Coll Cardiol. 1997;29:941 - 947.
Iversen HK. N-acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses.
Clin Pharmacol Ther. 1992;52:125 - 133.
Hogan JC, Lewis MJ, Henderson AH. Chronic administration of N-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris.
Br J Clin Pharmacol.
1990;30:573 - 577.
May DC, Popma JJ, Black WH, et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries.
N Engl J Med.
1987;317:805 - 809.
Ghio S, de Servi S, Perotti R, et al. Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Effects of
N
-acetylcysteine administration.
Circulation.
1992;86:798 - 802.
Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group.
Chest. 1997;112:164 - 172.
Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.
N Engl J Med.
2000;343:180 - 184.
Estensen RD, Levy M, Klopp SJ, et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps.
Cancer Lett.
1999;147:109 - 114.
Kinscherf R, Fischbach T, Mihm S, et al.Effect of glutathione depletion and oral N-acetyl-cysteine treatment on CD4+ and CD8+ cells.
FASEB J. 1994;8:448 - 451.
Akerlund B, Jarstrand C, Lindeke B, et al. Effect of N-acetylcystine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial.
Eur J Clin Pharmacol. 1996;50:457-461.
Look MP, Rockstroh JK, Rao GS, et al. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study
. Eur J Clin Invest . 1998;28:389 - 397.
Walker RE, Lane HC, Boenning CM, et al. The safety, pharmacokinetics, and antiviral activity of N-acetylcysteine in HIV-infected individuals [abstract].
J CellBiochem Suppl.
1992;16:89.
Akerlund B, Tynell E, Bratt G, et al. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary
Pneumocystiscarinii
prophylaxis in HIV-infected patients.
J Infect.
1997;35:143 - 147.
Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in
Pneumocystis carinii
pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:498 - 505.
van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and n-acetylcysteine in patients with head and neck cancer or lung cancer.
J Natl Cancer Inst.
2000;92:977 - 986.
Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term
N
-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Clin Ther.
2000;22:209 - 221.
Hansen NCG, Skriver A, Brorsen-Riis L, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Respir Med. 1994;88:531 - 535.
Grassi C, Casali L, Rossi A, et al. A comparison between different methods for detecting bronchial hyperreactivity. Bronchial hyperreactivity: methods of study.
Eur J Respir Dis Suppl. 1980;106:19 - 27.
Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.
Eur J Clin Pharmacol. 1976;9:393 - 396.
Riise GC, Larsson S, Larsson P, et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy?
Eur Respir J. 1994;7:94 - 101.
Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Eur Respir J. 1988;1:351 - 355.
Parr GD, Huitson A. Oral fabrol (oral N-acetylcysteine) in chronic bronchitis.
Br J Dis Chest. 1987;81:341 - 348.
Boman G, Bcker U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis. 1983;64:405 - 415.
Verstraeten JM. Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparaive clinical trial with N-acetylcysteine, bromhexine and placebo.
Acta Tuberc Pneumol Belg. 1979;70:71 - 80.
Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris.
J Am Coll Cardiol. 1997;29:941 - 947.
Iversen HK. N-acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses.
Clin Pharmacol Ther. 1992;52:125 - 133.
Pizzulli L, Hagendorff A, Zirbes M, et al. N-acetylcysteine attenuates nitroglycerin tolerance in patients with angina pectoris and normal left ventricular function.
Am J Cardiol. 1997;79:28 - 33.
Hogan JC, Lewis MJ, Henderson AH. Chronic administration of N-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris.
Br J Clin Pharmacol. 1990;30:573 - 577.
Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group.
Chest. 1997;112:164 - 172.
Estensen RD, Levy M, Klopp SJ, et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps.
Cancer Lett. 1999;147:109 - 114.
Kinscherf R, Fischbach T, Mihm S, et al.Effect of glutathione depletion and oral N-acetyl-cysteine treatment on CD4+ and CD8+ cells.
FASEB J. 1994;8:448 - 451.
Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad C, Rasool O. Effect of N-acetylcystine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial.
Eur J Clin Pharmacol. 1996;50:457-461.
Look MP, Rockstroh JK, Rao GS, et al. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study
. Eur J Clin Invest . 1998;28:389 - 397.
Walker RE, Lane HC, Boenning CM, et al. The safety, pharmacokinetics, and antiviral activity of N-acetylcysteine in HIV-infected individuals [abstract].
J CellBiochem Suppl.
1992;16:89.
Badawy AH, Abdel Aal SF, Samour SA. Liver injury associated with N-acetylcysteine administration.
J Egypt Soc Parasitol.1989;19:563 - 571.
Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
Neurology.
2001;57:1515-1517.
Hjortso E, Fomsgaard JS, Fogh-Andersen N. Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally?
Eur J Clin Pharmacol.
1990;39(1):29-31.
Tepel M, Zidek W. Acetylcysteine and contrast media nephropathy.
Curr Opin Nephrol Hypertens.
2002;11:503-506.
Walters MT, Rubin CE, Keightley SJ, et al. A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome.
Scand J Rheumatol Suppl.
1986;61:253-258.
Yalcin E, Altin F, Cinhuseyinoglue F. et al. N-acetylcysteine in chronic blepharitis.
Cornea.
2002;21:164-168.
Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non-paracetamol-induced).
Hepatogastroenterology
2000;47:786 - 789.
Van Schooten FJ, Besarati Nia A, De Flora S, et al. Effects of Oral Administration of N-Acetyl-L-cysteine: A Multi-Biomarker Study in Smokers.
Cancer Epidemiol Biomarkers Prev.
2002;11:167-175.
Holoya PY, Duelge J, Hansen RM,. Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Sem Oncol. 1983;10(Suppl 1):66 - 71.
Slavik M, Saiers JH. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
Sem Oncol. 1983;10(suppl 1):62 - 65.
Loehrer PJ, Williams SD, Einhorn LH. N-Acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Sem Oncol. 1983;10(Suppl 1):72 - 75.
Morgan LR, Donley PJ, Harrison EF. The control of ifosfamide induced hematuria with N-acetylcysteine.
Proc Am Assoc Cancer Res. 1981;22:190.
De Blasio F et al. N-acetyl cysteine (NAC) in preventing nausea and vomiting induced by chemotherapy in patients suffering from inoperable non small cell lung cancer (NSCLC).
Chest. 1996;110(Suppl 4):103S.
Medved I, Brown MJ, Bjorksten AR, et al. N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans.
J Appl Physiol. 2003;94:1572 - 1582.
Último revisado julio 2012 por EBSCO CAM Review Board
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.
Copyright © EBSCO Publishing. All rights reserved.